Dyne Therapeutics, Inc. (DYN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$24.28-2.69%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · DYN
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | |||||||
| R&D Expenses | 445.7 | 398.3 | 281.4 | 210.8 | 142.8 | 121.3 | 45.2 |
| Other Operating Expenses, Total | (0.2) | (1.7) | (0.5) | (1.4) | (0.1) | (0.0) | — |
| Operating Income | (537.0) | (468.2) | (343.9) | (242.2) | (171.0) | (150.0) | (58.6) |
| Earnings from Continuing Operations | |||||||
| Asset Writedown | — | — | — | — | — | 0.0 | 0.0 |
| Income Tax Expense | — | — | — | 0.0 | — | — | — |
| Net Income | |||||||
| Net Income | (73.2) | (446.2) | (317.4) | (0.0) | (0.0) | (149.3) | (59.4) |
| Per Share | |||||||
| Basic EPS | — | (3.47) | (3.37) | (3.95) | (3.23) | (2.93) | — |
| Diluted EPS | — | (3.47) | (3.37) | (3.95) | (3.23) | (2.93) | — |
| Supplemental | |||||||
| EBITDA | — | (466.1) | (342.2) | (240.5) | (169.3) | (148.9) | (57.9) |
| EBIT | (537.0) | (468.2) | (343.9) | (242.2) | (171.0) | (150.0) | (58.6) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.